Thyroid Cancer: Burden of Illness and Management of Disease

por Brown, Rebecca L., de Souza, Jonas A., Cohen, Ezra EW
Publicado 2011

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate...

por Burtness, Barbara, Bourhis, Jean P, Vermorken, Jan B, Harrington, Kevin J, Cohen, Ezra EW
Publicado 2014

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell ca...

por Machiels, Jean-Pascal H, Licitra, Lisa F, Haddad, Robert I, Tahara, Makoto, Cohen, Ezra EW
Publicado 2014

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and...

por Cohen, Ezra EW, Moore, Kathleen N, Slomovitz, Brian M, Chung, Christine H, Anderson, Matthew L, Morris, Shannon R, Mauro, David, Burtness, Barbara
Publicado 2015

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer

por Fordham, Beth A, Kerr, Cicely, de Freitas, Hayley M, Lloyd, Andrew J, Johnston, Karissa, Pelletier, Corey L, Tremblay, Gabriel, Forsythe, Anna, McIver, Bryan, Cohen, Ezra EW
Publicado 2015

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

por Pederson, Aaron W, Salama, Joseph K, Haraf, Daniel J, Witt, Mary Ellen, Stenson, Kerstin M, Portugal, Louis, Seiwert, Tanguy, Villaflor, Victoria M, Cohen, Ezra EW, Vokes, Everett E, Blair, Elizabeth A
Publicado 2011

Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4(+) T cells

por Brightman, Spencer E., Naradikian, Martin S., Thota, Rukman R., Becker, Angelica, Montero, Leslie, Bahmanof, Milad, Premlal, Ashmitaa Logandha Ramamoorthy, Greenbaum, Jason A., Peters, Bjoern, Cohen, Ezra E.W., Miller, Aaron M., Schoenberger, Stephen P.
Publicado 2023

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

por Taylor, Matthew H., Betts, Courtney B., Maloney, Lauren, Nadler, Eric, Algazi, Alain, Guarino, Michael J., Nemunaitis, John, Jimeno, Antonio, Patel, Priti, Munugalavadla, Veerendra, Tao, Lin, Adkins, Douglas, Goldschmidt, Jerome H., Cohen, Ezra E.W., Coussens, Lisa M.
Publicado 2022

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies

por Karovic, Sanja, Wen, Yujia, Karrison, Theodore G., Bakris, George L., Levine, Matthew R., House, Larry K., Wu, Kehua, Thomeas, Vasiliki, Rudek, Michelle A., Wright, John J., Cohen, Ezra E.W., Fleming, Gini F., Ratain, Mark J., Maitland, Michael L.
Publicado 2014

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

por Cohen, Ezra E.W., Nabell, Lisle, Wong, Deborah J., Day, Terry, Daniels, Gregory A., Milhem, Mohammed, Deva, Sanjeev, Jameson, Michael, Guntinas-Lichius, Orlando, Almubarak, Mohammed, Strother, Matthew, Whitman, Eric, Chisamore, Michael, Obiozor, Cynthia, Bagulho, Teresa, Gomez-Romo, Jose, Guiducci, Cristiana, Janssen, Robert, Gamelin, Erick, Algazi, Alain P.
Publicado 2022

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

por Gutkind, J. Silvio, Molinolo, Alfredo A., Wu, Xingyu, Wang, Zhiyong, Nachmanson, Daniela, Harismendy, Olivier, Alexandrov, Ludmil B., Wuertz, Beverly R., Ondrey, Frank G., Laronde, Denise, Rock, Leigha D., Rosin, Miriam, Coffey, Charles, Butler, Valerie D., Bengtson, Lisa, Hsu, Chiu-Hsieh, Bauman, Julie E., Hewitt, Stephen M., Cohen, Ezra E.W., Chow, H-H. Sherry, Lippman, Scott M., Szabo, Eva
Publicado 2021